Pulseless electrical activity risk factors: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Pulseless electrical activity}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}}") |
|||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Risk Factors== | |||
The administration of [[beta blockers]] and [[calcium channel blockers]] is associated with an increased risk of PEA. This may be due to their effect on Ca / troponin interactions, and their inhibition of myocardial contractility. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 13:26, 17 September 2012
Pulseless electrical activity Microchapters |
Differentiating Pulseless Electrical Activity from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Pulseless electrical activity risk factors On the Web |
American Roentgen Ray Society Images of Pulseless electrical activity risk factors |
Directions to Hospitals Treating Pulseless electrical activity |
Risk calculators and risk factors for Pulseless electrical activity risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk Factors
The administration of beta blockers and calcium channel blockers is associated with an increased risk of PEA. This may be due to their effect on Ca / troponin interactions, and their inhibition of myocardial contractility.